13.07.2015 Views

Application for the Reassessment of a Hazardous Substance under ...

Application for the Reassessment of a Hazardous Substance under ...

Application for the Reassessment of a Hazardous Substance under ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

―It is considered that <strong>the</strong> most suitable endpoint <strong>for</strong> estimation <strong>of</strong> occupational risks <strong>for</strong>dermal exposures is an oral NOEL <strong>of</strong> 0.014 mg/kg bw/d[ay], established in <strong>the</strong> 28-d[ay]oral study in humans by Rider (1967). The study is highly suitable because itdemonstrated a NOEL and a LOEL <strong>for</strong> plasma ChE inhibition and was per<strong>for</strong>med withhuman subjects, <strong>the</strong>reby eliminating uncertainty associated with inter-speciesextrapolation. Adjusting <strong>for</strong> a dermal absorption factor <strong>of</strong> 30%, <strong>the</strong> resulting dermalNOEL becomes 0.047 mg/kg bw/d[ay]. The acceptable margin <strong>of</strong> exposure (MOE) is >10, resulting from application <strong>of</strong> a 10-fold uncertainty factor <strong>for</strong> intra-speciesvariability. No correction <strong>for</strong> an internal dose is required since absorption from <strong>the</strong> GITis almost complete (93 – 96%).Dichlorvos reassessment – application Page 270 <strong>of</strong> 436

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!